fatty liver disease
Coverage of fatty liver disease in the Nexus archive.
- Cutting GLP-1 coverage may cost UVM Health more than it saves
UVM Health is considering eliminating GLP-1 medication coverage for weight management to save $19 million annually. The author argues this decision overlooks long-term healthcare cost savings from improved patient outcomes, such as reduced specialist visits and chronic disease risks.
- Experimental drug reverses severe fatty liver disease by repairing the gut
An experimental drug called DT-109 reversed severe fatty liver disease in animal studies by repairing the gut and preventing harmful toxins from damaging the liver. The discovery could lead to new treatments for MASH and other gut-related diseases.
- Two common drugs may reverse fatty liver disease, study finds
Scientists found that combining two existing drugs can significantly reduce liver fat associated with a common, often silent disease in animal models. The treatment also showed potential to lower heart-related risks and worked effectively with lower doses. However, human trials are needed to confirm these findings.
- Scientists remove “zombie” cells and reverse liver damage in mice
Scientists identified 'zombie' immune cells that accumulate with age and high cholesterol, contributing to liver inflammation and damage. Removing these cells in mice reversed liver damage without dietary changes, offering potential insights for treating aging-related and metabolic diseases.